Alzheimers & Huntingtons (Drugs)

Question 1

Tetrabenazine

Answer 1

Huntington Disease Treatment

MAO:
Inhibits monoamine vesicle transport reduces Dopamine storage/release
–> Decreases Dopamine

Question 2

Chlorpromazine

Answer 2

Dopamine Receptor Antagonist
- Huntington Disease Treatment

MOA:
- Decreases binding to Dopamine Receptor
–> Decrease Dopamine Activity

Question 3

Baclofen

Answer 3

GABA(B) Receptor Agonist
- Treats Huntington’s Disease

MOA:
- Binds to GABA(B) receptor
- Lowers neuronal activity
–> Decrease Dopamine

Question 4

Donepezil

Answer 4

Cholinesterase Inhibitors (CNS)
- Alzheimer’s Disease Treatment

MOA:
- Prevents ACh breakdown
–> Increase Ach working against cholinergic deficit

Question 5

Rivastigmine

Answer 5

Cholinesterase Inhibitors (CNS)
- Alzheimer’s Disease Treatment

MOA:
- Prevents ACh breakdown
–> Increase Ach working against cholinergic deficit

Question 6

Galantamine

Answer 6

Cholinesterase Inhibitors (Does not Enter CNS)
- Alzheimer’s Disease Treatment

MOA:
- Prevents ACh breakdown
–> Increase Ach working against cholinergic deficit

Question 7

Tacrine

Answer 7

Cholinesterase Inhibitors (Does not Enter CNS)
- Alzheimer’s Disease Treatment

MOA:
- Prevents ACh breakdown
–> Increase Ach working against cholinergic deficit

Question 8

Memantine

Answer 8

NMDA Receptor Channel Blocker
(Non-Competitive Antagonist)
- Alzheimer’s Disease Treatment

MOA:
- Blocks NMDA receptor
–> Prevents excitotoxicity